Advicenne updated the progress of the partnerships signed during 2022 in Europe and the Middle East for the marketing of Sibnayal® (a fixed dose combination of potassium citrate and potassium bicarbonate). Advicenne and its partner for the Nordic and the Baltic countries, Frost Pharma, have recently achieved their first major successes, where in Norway physicians can now prescribe Sibnayal® with an official price since 1st February.
In Sweden, TLV (Tandvårds- och LäkemedelsförmånsVerket), the drug management agency, has just rejected the application for national reimbursement and leave Swedish hospitals to finance the product on their own budget. Patients already on Sibnayal via the temporary access program, will now need to be transferred to hospital paid treatment, as well as new patients switched to Sibnayal from other therapies. In other European countries, Advicenne's commercial partners are also making significant progress. In Belgium, Twin Pharma has obtained a price and is now in the process of getting reimbursement for Sibnayal. In Central and Eastern Europe, ExCEEd Orphan is focusing primarily on setting up early access programs and with the first patients included in Croatia, the Czech Republic, Slovakia, and Bulgaria. The strategy is similar for Taïba Healthcare in the Middle East, where early access programs are being set up to establish initial market access. At the same time, Taïba Healthcare and Advicenne are preparing to file a registration application in Saudi Arabia and United Arab Emirates.